RESI Conference (Redefining Early-Stage Investments)

by Biolexis | Sep 27, 2022 | News & Media

September 21-22, 2022

Biolexis Therapeutics Business Development Director Kyle Medley participated in RESI Conference (Redefining Early-Stage Investments), Boston, MA on Sep 21-22, 2022.

https://resiconference.com/

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

October 26, 2023 Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the...

SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD

November 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E....

INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

October 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer...

« Older Entries

RESI Conference (Redefining Early-Stage Investments)

September 21-22, 2022

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD

INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

Admissions Consult Application: We're more interested in potential and determination than GPA

CDK9